Navigation Links
Inverseon Focuses on Mucous and Smoking Cessation
Date:1/12/2012

SAN FRANCISCO, Jan. 12, 2012 /PRNewswire/ -- Inverseon, Inc., a pharmaceutical company developing drug therapies for the treatment of pulmonary disorders, announced that while it anticipates that its asthma program will advance with non-dilutive grants, it is focused on smoking cessation as the initial indication for INV102.

William J. Garner, MD, Chairman, said, "The prioritization of smoking cessation, and also an inhaled COPD program, makes sense for Inverseon given the regulatory hurdles in key markets. We credit Dr. Glass for this refinement of our priorities. Mitchell Glass's extensive drug development background, relationships with the respiratory community, and experience with the strategic development and commercialization of therapeutics will be a major asset for Inverseon as the company advances its lead product (INV102) towards commercialization."

"Inverseon has provided critical support for the use of beta-adrenergic receptor inverse agonists for treating respiratory diseases. The founder's basic scientific breakthroughs provide a rational explanation for our previous success in developing carvedilol for heart failure while I was at SmithKline Beecham and provide a rationale for using INV102 for treating COPD. Two Phase II asthma trials are supportive of further development for chronic pulmonary diseases," said Dr. Glass. "We are now collaborating with granting agencies for further development of INV102 in asthma and preparing for expanded internal Phase II clinical trials demonstrating safety and efficacy of INV102 as a treatment to aid smoking cessation and chronic bronchitis."

About Inverseon, Inc.
Founded in 2004, Inverseon is a privately held company with product development programs in Phase II that target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as COPD and asthma. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects "Paradoxical Pharmacology," based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon's website at http://www.inverseon.com.

Forward-Looking Statement
This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Contact:

William J. Garner, MD
bill@inverseon.com  
http://www.inverseon.com  
(917) 653-0470

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Inverseon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
2. Nature article focuses on tinnitus treatment
3. ONR lecture focuses on Brazils growth in global science and technology
4. Florida Water Resources Annual Conference Focuses on Numeric Nutrient and Other Water Issues
5. Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform
6. Nanomedicine Company Focuses on Improving Premature Infant Health and Reducing Death Rate
7. Jivan Focuses on Solutions for Transcriptome Sequencing
8. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
9. Siemens Focuses on Role-Based, Context-Sensitive, and Knowledge-Driven Solutions at HIMSS 2009
10. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
11. ECBCs Environmental BioMonitoring Laboratory Focuses on the Future
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... the business of innovation is taking over sports. On Thursday, December 15th a ... how technology is disrupting the playing field at a Smart Talk session. Smart ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, ... The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard 204-pin ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
Breaking Biology Technology:
(Date:11/28/2016)... LONDON , Nov. 28, 2016 ... at a rate of 16.79%" The biometric system ... to grow further in the near future. The biometric ... 32.73 billion in 2022, at a CAGR of 16.79% ... biometrics system, integration of biometric technology in smartphones, rising ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):